Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    4D Molecular Therapeutics, Inc. (FDMT) Insider Trading Activity

    Healthcare • Biotechnology • 201 employees

    4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

    Total Value

    -$363,374.72

    Total Shares

    0

    Average Trade Value

    -$18,168.74

    Most Active Insider

    Kirn David

    Total Activity: $963,837

    Largest Single Transaction

    $298,711

    by Kirn David on Jun 24, 2024

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    Chief Legal Officer
    Sep 16, 2024 500 $3,245 7,281 (+6.9%) Exercise/Conversion
    Chief Legal Officer
    Sep 16, 2024 500 $8,165 6,781 (-7.4%) Sale
    Chief Legal Officer
    Aug 19, 2024 500 $7,500 6,781 (-7.4%) Sale
    Chief Legal Officer
    Aug 19, 2024 500 $3,245 7,281 (+6.9%) Exercise/Conversion
    Chief Legal Officer
    Jul 16, 2024 500 $3,245 7,281 (+6.9%) Exercise/Conversion
    Chief Legal Officer
    Jul 16, 2024 1,250 $10,050 8,531 (+14.7%) Exercise/Conversion
    Chief Legal Officer
    Jul 16, 2024 1,750 $47,443 6,781 (-25.8%) Sale
    Chief Legal Officer
    Jul 11, 2024 1,996 $31,497 8,777 (+22.7%) Exercise/Conversion
    Chief Legal Officer
    Jul 11, 2024 1,996 $49,900 6,781 (-29.4%) Sale
    Chief Executive Officer
    Jul 10, 2024 1,270 $20,041 1,072,076 (+0.1%) Exercise/Conversion
    Chief Executive Officer
    Jul 10, 2024 11,653 $168,036 1,070,806 (+1.1%) Exercise/Conversion
    Chief Executive Officer
    Jul 10, 2024 12,923 $290,598 1,059,153 (-1.2%) Sale
    Chief Legal Officer
    Jul 1, 2024 2,916 $23,445 5,985 (+48.7%) Exercise/Conversion
    Chief Legal Officer
    Jul 1, 2024 4,248 $90,758 1,737 (-244.6%) Sale
    Chief Legal Officer
    Jul 1, 2024 1,332 $8,645 3,069 (+43.4%) Exercise/Conversion
    Chief Executive Officer
    Jun 24, 2024 12,930 $298,711 1,059,153 (-1.2%) Sale
    Chief Executive Officer
    Jun 24, 2024 12,930 $186,451 1,072,083 (+1.2%) Exercise/Conversion
    Chief Legal Officer
    Jun 17, 2024 500 $3,245 2,237 (+22.4%) Exercise/Conversion
    Chief Legal Officer
    Jun 17, 2024 1,750 $41,494 1,737 (-100.7%) Sale
    Chief Legal Officer
    Jun 17, 2024 1,250 $10,050 3,487 (+35.8%) Exercise/Conversion